A Phase 3 interventional study of T790M+ Testing and Baseline Visit Blood & Urine Testing in Lung Cancer, sponsored by AstraZeneca. Completed at 201 sites in 16 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-11-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing osimertinib in Lung Neoplasms — 10 open to participants now, 18 under way, 2 of them phase 3. osimertinib · Lung Neoplasms.
Among the 30 studies testing osimertinib in Lung Neoplasms, this one is the 2nd largest by enrollment, is one of 4 that started in 2015, is one of 4 in phase 3, and was the 2nd registered.
5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →10 of the 30 studies testing osimertinib in Lung Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–99
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
Samsung Medical Center · Sites in Korea, Republic of
Ages 30–75
By country, each count listing its studies:
osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, osimertinib is the treatment under test here. Read study by study →
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 19 · Phase 3 4 · Phase 4 1
First in 2014; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,017 is above the median of 60 across 3,657 interventional studies indexed under Lung Neoplasms.
Median enrollment 52 across the 30 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 30 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
63 studies in Lung Neoplasms by AstraZeneca: 12 open now, 22 under way, 3 of them phase 3. Of 39 finished, 13 (33%) have results posted.
Among the 63 studies in Lung Neoplasms by AstraZeneca, this one has the largest enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2015, is one of 9 in phase 3, and was the 24th registered.
AstraZeneca’s Lung Neoplasms studies by the year they started, since 2000.
4 of the studies testing osimertinib in Lung Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04285671Jonsson Comprehensive Cancer CenterNecitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | 2026-12-02 |
| NCT03567642Memorial Sloan Kettering Cancer CenterA Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers | 2027-06 |
| NCT02496663National Cancer Institute (NCI)Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor | 2027-06-30 |
| NCT04591002Samsung Medical CenterOsimertinib to Suppress the Progression of GGN(EGFR Mutation-positive) | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing osimertinib in Lung Neoplasms, from their registry updates:
Among AstraZeneca’s 63 in Lung Neoplasms:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.
Objective: The primary objective of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.
Study site(s) and number of patients planned: Approximately 1500 patients will be recruited in Europe. The recruitment will be increased beyond that as the study will expand in other regions of the world (America, Asia).
Study Design This will be an open-label, single-arm, multinational, multicenter, real world treatment study.
Target patient population: Adult patients (fulfilling the definition of "age of majority" per local regulations) with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC with confirmed T790M mutation, who have received prior EGFR-TKI therapy.
Investigational product (IP), dosage, and mode of administration: AZD9291 is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitising and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. AZD9291 will be administered orally as one 80 mg tablet once a day.
Duration of IP administration: Patients may continue to receive AZD9291 as long as they continue to show clinical benefit, as judged by the investigator, and in the absence of discontinuation criteria). The study will be closed in each participating country as soon as possible following national reimbursement of AZD9291 in that country (up to a max of 90 days post reimbursement). Enrolment will be closed within 6 months after market license approval in that country or at national reimbursement, whichever is sooner. Patients withdrawing from the treatment prior to national reimbursement will be followed up as part of this study. Patients on treatment will receive commercial supply until documented disease progression as per investigator assessment.
In the event that national reimbursement should not be granted following a reasonable time after market license approval in the country, the study will be closed in a maximum period of 18 months after the last patient is enrolled in that country. If applicable, timelines for conversion to commercial drug will be agreed with local bodies which may include regulatory agencies, ethics committees, and institutions. Patient will be followed until death or lost to follow-up.
Study measures: Data collected will include patient demographics, information needed to determine patient eligibility (including medical history, past and current disease characteristics, and tumor EGFR mutational status), AZD9291 exposure, investigator-reported efficacy (including tumor response and disease progression), overall survival (OS), and safety (including serious adverse events [SAEs], adverse events leading to dose modification, and adverse events of special interest [interstitial lung disease/pneumonitis-like events, and QTc prolongation events]).
Statistical methods: All data will be presented for the overall full analysis/evaluable set, and also by cohorts defined by number and type of previous treatment lines for the advanced disease. Descriptive statistics will be used for all variables, as appropriate. Continuous variables will be summarised by the number of observations, mean, standard deviation, median, minimum, and maximum. Categorical variables will be summarised by frequency counts and percentages for each category. OS and PFS will be summarized using Kaplan-Meier estimates of the median time to death or censoring and quartiles together with their 95% confidence intervals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following cardiac criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm of AZD9291, starting dose of 80mg
Procedure: T790M+ Testing · Procedure: Baseline Visit Blood & Urine Testing · Procedure: Baseline ECG · Procedure: Visual Slit-Lamp Testing · Drug: AZD9291 Dosing
If a previous lab report is unavailable, the patient will need to have T790M+ testing.
Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
ECG to ensure absence of any cardiac abnormality
Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Overall Survival (OS)
OS was defined as the time, in months from the date of first dose of Osimertinib until death due to any cause, or at last documented contact with participant status "alive" (in this study any participants alive at study discontinuation, or lost to follow-up was considered being censored at study discontinuation date or at the last known date participant was alive). OS was summarized using a Kaplan-Meier (KM) estimate of the median time to death or censoring together with their 95% confidence intervals.
Time frame: From the date of first dose of Osimertinib until the date of death (due to any cause) or last participant contact [up to 43 months]
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Safety assessment of Osimertinib was analyzed by evaluating AEs and SAEs.
Time frame: From screening to progression follow-up [every 6 weeks +/- 1 week] relative to the date of enrolment until the end of study [up to 43 months]
Progression Free Survival
PFS was defined as the time, in months from first dose of AZD9291/ost/study drug/ study treatment until the date of disease progression or death in the absence of progression. Participants who had not progressed or died at study discontinuation were censored at the time of the latest date of disease assessment. PFS was summarized using KM estimates of the median time to progression or death with their 95% confidence intervals.
Time frame: From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Time to Treatment Discontinuation (TTD)
TTD or death was assessed as a supportive summary to PFS and defined as the time from the date of the first dose of osimertinib in the study until the date of osimertinib discontinuation or death, regardless of the reason for discontinuation. TTD was summarized using KM estimates of the median times to progression or death or treatment discontinuation.
Time frame: From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Response Rate (RR)
RR was defined as the number (%) of participants with a best response (by Investigator assessment) of 'responding', regardless of the method of evaluation, and was based on a subset of the full analysis set consisting of subjects with at least one documented response assessment. RR was summarised together with the 95% CI.
Time frame: From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Participants who met all the inclusion and none of the exclusion criteria received treatment in a total of 209 centres in 16 countries. The study started on 18 September 2015 and primary completion date was 18 April 2019.
| Milestone | Osimertinib |
|---|---|
| Started | 3014 |
| Completed | 1386 |
| Not completed | 1628 |
| Withdrew: Other | 43 |
| Withdrew: Eligibility criteria not fulfilled | 2 |
| Withdrew: Lost to follow-up | 98 |
| Withdrew: Withdrawal by subject | 124 |
| Withdrew: Death | 1361 |
OS was defined as the time, in months from the date of first dose of Osimertinib until death due to any cause, or at last documented contact with participant status "alive" (in this study any participants alive at study discontinuation, or lost to follow-up was considered being censored at study discontinuation date or at the last known date participant was alive). OS was summarized using a Kaplan-Meier (KM) estimate of the median time to death or censoring together with their 95% confidence intervals.
| Months | Osimertinib |
|---|---|
| Overall Survival (OS) | 22.8 (21.6 to 23.8) |
Safety assessment of Osimertinib was analyzed by evaluating AEs and SAEs.
| Participants | Osimertinib |
|---|---|
| AE of special interest (AESI) or SAE | 923 |
| AESI or SAE a causally related to Osimertinib | 338 |
| AE leading to dose modification | 414 |
| AE leading to discontinuation | 191 |
| AESI | 113 |
| AESI causally related to Osimertinib | 89 |
| SAE | 657 |
| SAE causally related to Osimertinib | 95 |
| AE leading to death | 152 |
| AE leading to death causally related to Osimertinib | 19 |
PFS was defined as the time, in months from first dose of AZD9291/ost/study drug/ study treatment until the date of disease progression or death in the absence of progression. Participants who had not progressed or died at study discontinuation were censored at the time of the latest date of disease assessment. PFS was summarized using KM estimates of the median time to progression or death with their 95% confidence intervals.
| Months | Osimertinib |
|---|---|
| Progression Free Survival | 11.1 (11.0 to 12.0) |
TTD or death was assessed as a supportive summary to PFS and defined as the time from the date of the first dose of osimertinib in the study until the date of osimertinib discontinuation or death, regardless of the reason for discontinuation. TTD was summarized using KM estimates of the median times to progression or death or treatment discontinuation.
| Months | Osimertinib |
|---|---|
| Time to Treatment Discontinuation (TTD) | 13.5 (12.6 to 13.9) |
RR was defined as the number (%) of participants with a best response (by Investigator assessment) of 'responding', regardless of the method of evaluation, and was based on a subset of the full analysis set consisting of subjects with at least one documented response assessment. RR was summarised together with the 95% CI.
| Percentage of participants | Osimertinib |
|---|---|
| Response Rate (RR) | 57.3 (55.5 to 59.2) |
Collected over From screening to progression follow-up [every 6 weeks +/- 1 week] relative to the date of enrolment until the end of study [up to 43 months]. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Osimertinib | 1,361/3,014 (45.2%) | 657/3,014 (21.8%) | 380/3,014 (12.6%) |
| Event | Osimertinib |
|---|---|
| PneumoniaInfections and infestations | 74/3014 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 49/3014 |
| DeathGeneral disorders | 34/3014 |
| Cerebral infarctionNervous system disorders | 22/3014 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 20/3014 |
| Deep vein thrombosisVascular disorders | 17/3014 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 15/3014 |
| VomitingGastrointestinal disorders | 13/3014 |
| DiarrhoeaGastrointestinal disorders | 12/3014 |
| PyrexiaGeneral disorders | 12/3014 |
| Event | Osimertinib |
|---|---|
| Electrocardiogram QT prolongedInvestigations | 88/3014 |
| DiarrhoeaGastrointestinal disorders | 30/3014 |
| ThrombocytopeniaBlood and lymphatic system disorders | 20/3014 |
| Platelet count decreasedInvestigations | 17/3014 |
| NeutropeniaBlood and lymphatic system disorders | 16/3014 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 13/3014 |
| NauseaGastrointestinal disorders | 11/3014 |
| ParonychiaInfections and infestations | 11/3014 |
| VomitingGastrointestinal disorders | 10/3014 |
| Aspartate aminotransferase increasedInvestigations | 10/3014 |
The full analysis set included all participants who received at least one dose of study treatment.
| Age, Categorical(Participants) | Osimertinib |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 1798 |
| >=65 years | 1216 |
| Age, Continuous(Years) | Osimertinib |
|---|---|
| Mean | 61.7 ± 10.91 |
| Sex: Female, Male(Participants) | Osimertinib |
|---|---|
| Female | 1927 |
| Male | 1087 |
| Race (NIH/OMB)(Participants) | Osimertinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2085 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 21 |
| White | 897 |
| More than one race | 0 |
| Unknown or Not Reported | 11 |
| Country(Participants) | Osimertinib |
|---|---|
| Argentina | 30 |
| Australia | 31 |
| Austria | 46 |
| Belgium | 31 |
| Brazil | 88 |
| Canada | 99 |
| China | 1350 |
| Denmark | 6 |
| Ireland | 10 |
| Italy | 510 |
| Saudi Arabia | 3 |
| South Korea | 466 |
| Spain | 131 |
| Sweden | 7 |
| Taiwan | 188 |
| United Kingdom | 18 |
Showing the first 100 of 201 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Apr 2019, 43 months.
Results were first posted in Oct 2021, 2 years 6 months after primary completion. A results delay was requested in Apr 2019.
Of 62 industry-sponsored phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 43 months is above that.
Counting every sponsor, half of 128 studies reached it within 44 months; a quarter within 30 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osimertinib